Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CN

NASDAQ · CNTB

Connect Biopharma Holdings Limited

Healthcare · Biotechnology

$2.04

Down-$0.02 (-0.97%)

Updated Sep 12, 2026, 4:48 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
136.39M
P/E ratio
-3.75
Dividend yield
0.00%
52-week range
$1.74 – $3.82
Volume
878.04K
Avg. volume
268.18K

Price performance

CNTB price history

1M range · 20 trading sessions · Daily adjusted prices

CNTB closed at $2.04 after 20 trading sessions, down 20.00% for the selected period.

Last close
$2.04
Period change
-20.00%
Period low
$1.84
Period high
$2.76
Daily close
View OHLC price history
CNTB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$2.07$2.0991$1.94$2.04878.04K
Sep 10, 2026$1.99$2.075$1.91$2.06768.57K
Sep 9, 2026$1.91$2.10$1.89$2.01963.89K
Sep 8, 2026$1.92$1.97$1.80$1.911.19M
Sep 4, 2026$2.00$2.03$1.74$1.842.41M
Sep 3, 2026$2.83$2.93$1.90$1.933.76M
Sep 2, 2026$2.37$2.8584$2.37$2.762.61M
Sep 1, 2026$2.20$2.415$2.15$2.361.98M
Aug 31, 2026$2.27$2.35$2.16$2.20571.35K
Aug 28, 2026$2.32$2.32$2.20$2.23340.77K
Aug 27, 2026$2.34$2.40$2.26$2.28551.68K
Aug 26, 2026$2.47$2.5026$2.33$2.33396.22K
Aug 25, 2026$2.33$2.48$2.33$2.45636.73K
Aug 24, 2026$2.38$2.38$2.25$2.30430.03K
Aug 21, 2026$2.30$2.37$2.21$2.36444.95K
Aug 20, 2026$2.48$2.62$2.26$2.28573.36K
Aug 19, 2026$2.49$2.578$2.44$2.46450.7K
Aug 18, 2026$2.50$2.57$2.415$2.43320.3K
Aug 17, 2026$2.57$2.61$2.47$2.49578.3K
Aug 14, 2026$2.54$2.57$2.36$2.55212.2K

Latest CNTB news

The latest Smart Investors Daily articles mentioning CNTB.

Stock researchCompany · Overview

CNTB research

Overview

Company profile and research snapshot.

Company profile

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
CNTB recent ratings
DateFirmRatingTarget
Jul 9, 2026OppenheimerOutperform—
Jun 26, 2026Piper SandlerOverweight—
Jun 25, 2026HC Wainwright & Co.Buy—
May 26, 2026Canaccord GenuityBuy—
May 21, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET. The live webcast of the presentation may be accessed v

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By